24
Participants
Start Date
October 31, 2006
Primary Completion Date
June 30, 2012
Study Completion Date
June 30, 2012
Vaccine Treatment
We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
Cyclophosphamide
Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
All-trans retinoic acid (ATRA)
All-trans retinoic acid was given (150/mg/m\^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
H. Lee Moffitt Cancer Center and Research Institute, Tampa
National Cancer Institute (NCI)
NIH
National Institutes of Health (NIH)
NIH
H. Lee Moffitt Cancer Center and Research Institute
OTHER